Raptor Pharmaceutical (RPTP) 11.18 $RPTP
Raptor Pharmaceutical to Present at Upcoming Investor Conference in September
GlobeNewswire - Wed Aug 27, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 10, 2014 at 11:30 a.m. EDT/8:30 a.m. PDT. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.
Global Nonalcoholic Steatohepatitis (NASH) Market - Research Report to 2020
M2 - Mon Aug 18, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2l26vd/global) has announced the addition of the "Global Nonalcoholic Steatohepatitis (NASH) Market (Pipeline analysis, drug class, clinical trials and Geography) - Research Report, 2013 - 2020" report to their offering. A new report entitled, "Nonalcoholic Steatohepatitis Market (Pipeline analysis, drug class and Geography) Global Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013 - 2020", indicates that the global nonalcoholic steatohepatitis (NASH) market would reach $1.6 billion by 2020 registering CAGR of 25.6% from 2014 to 2020. The high prevalence of Type II diabetes and obesity, which lead to NASH and other non-alcoholic fatty liver diseases (NAFLD), would boost market growth. North America's heightened focus on NASH research has resulted in it accounting for nearly half of the global market. It is also the region with the maximum occurrences of NASH and other non-alcoholic fatty liver diseases. Europe ranks second in terms of the prevalence of NASH. The number of patients living with the diabetes worldwide is expected to soar from 371 million in 2012 to 552 million by 2030. This suggests that by 2030, there will be 3 new cases of diabetes every 10 seconds. "The rampant growth of diabetes and obesity has prompted pharmaceutical manufacturers to seek out novel pharmaceutical solutions to tap promising potential in NASH," states AMR analyst Roshan Deshmukh. "Instrumental initiatives and increasing clinical trials for the development of novel NASH therapeutics will steer its faster commercialization," adds the analyst. Key Topics Covered: CHAPTER 1 NTRODUCTION CHAPTER 2 EXECUTIVE SUMMARY CHAPTER 3 MARKET BEYOND: WHAT TO EXPECT BY 2025 CHAPTER 4 MARKET OVERVIEW CHAPTER 5 GLOBAL NONALCOHOLIC STEATOHEPATITIS MARKET BY DRUG TYPES CHAPTER 6 GLOBAL NONALCOHOLIC STEATOHEPATITIS MARKET (PIPELINE DRUG ANALYSIS)BY GEOGRAPHY, 2013-20206 CHAPTER 7 COMPANY PROFILES Companies Mentioned: - Enzo Biochem - Genfit - Gilead Science - Intercepts Pharmaceuticals - Novo Nordisk - Raptor Pharmaceutical Corp. For more information visit http://www.researchandmarkets.com/research/2l26vd/global
Raptor Pharmaceuticals (RPTP) Jumps: Stock Adds 28.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 8:39AM CDT
Raptor Pharmaceuticals Corp. (RPTP) was a big mover last session, as its shares rose over 28% on the day.
Why Raptor Pharmaceuticals (RPTP) Stock Is Gaining Today
at The Street - Fri Aug 08, 10:58AM CDT
Raptor Pharmaceuticals (RPTP) is gaining Friday after beating analysts' estimates for earnings and revenue in the second quarter and raising its sales guidance for the year.
Raptor Pharmaceutical Reports Second Quarter 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Global net product sales for PROCYSBI of $16.3 million reported for second quarter 2014
Raptor Pharmaceutical to Present at Upcoming Investor Conference
GlobeNewswire - Wed Aug 06, 3:51PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Canaccord Genuity Annual Growth Conference in Boston on Wednesday, August 13, 2014 at 5:00 p.m. EDT/2:00 p.m. PDT. Georgia Erbez, CFO of Raptor, will present an update on the company's commercial activities and clinical programs. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.
Raptor Receives Orphan Drug Designation for Cysteamine Bitartrate in Huntington's Disease From the European Commission
GlobeNewswire - Mon Aug 04, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the European Commission (EC) approved its application for orphan drug designation of cysteamine bitartrate, the active ingredient in RP103, for the treatment of Huntington's disease. The decision follows a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) in June. In February of this year, Raptor announced encouraging top line results from a planned 18-month analysis of the blinded, randomized, placebo-controlled phase of its ongoing CYST-HD clinical trial of RP103, its proprietary delayed release cysteamine bitartrate capsule, in patients with early-stage Huntington's disease.
The Federal Reserve Playing Analyst Damaging to Biotechnology Companies
ACCESSWIRE - Wed Jul 30, 9:06AM CDT
WHITEFISH, MT / July 30, 2014 / The July 15 U.S. Federal Reserve report on monetary policy touched off a barrage of barely polite and not very muted commentary from one end of the web to the other this past week with 32 simple words: "Equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched, with ratios of prices to forward earnings remaining high relative to historical norms." The release of the report to Congress coincided with the start of Federal Reserve Chairwoman Janet Yellen's testimony before a Congressional committee. NBI, the Nasdaq Biotechnology Index, slumped from around 2,700 on Tuesday to a low of 2,536 on Thursday, a 6% nosedive, before paring the losses with an up day on Friday. Of the 120 companies in the NBI, 101 closed in the red last week, including Ligand Pharma (NASDAQ: LGND) shedding 19.4% and Raptor Pharma (NASDAQ: RPTP) falling 18.7%.
Raptor Pharmaceutical to Hold Second Quarter 2014 Financial Results Webcast and Conference Call
GlobeNewswire - Mon Jul 28, 3:15PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release second quarter 2014 financial results after market close on Thursday, August 7, 2014. Raptor management will host a webcast and conference call at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update.
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic
ACCESSWIRE - Thu Jul 24, 9:03AM CDT
WHITEFISH, MT / July 24, 2014 / Fat is driving the bus these days in one narrow, but widening, biotech sector as companies strive for dominance. Among these are Galectin Therapeutics Inc. (NASDAQ: GALT), Intercept Pharmaceuticals (NASDAQ: ICPT), Raptor Pharmaceuticals (NASDAQ: RPTP) and Gilead Sciences (NASDAQ: GILD), all of which are in search of a cure for one stage or another of "fatty liver disease."
Executive Appointments and Technical Updates - Analyst Notes on Aeri Pharmaceuticals, DaVita, Prana Biotechnology, Raptor and Avanir Pharmaceuticals
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Aeri Pharmaceuticals, Inc. (NASDAQ: AERI), DaVita HealthCare Partners Inc. (NYSE: DVA), Prana Biotechnology Ltd. (NASDAQ: PRAN), Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) and Avanir Pharmaceuticals (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4726-100free.
3 Stocks Spiking on Unusual Volume
at The Street - Thu Jul 10, 8:14AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Raptor Pharmaceuticals CEO to Retire, Appoints Successor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 4:10PM CDT
Raptor Pharma (RPTP) announced a change at the helm.
Raptor Announces CEO Succession Plan; Dr. Christopher Starr to Retire as CEO at Year-end 2014, Julie Anne Smith Named President and CEO-Designate
GlobeNewswire - Mon Jul 07, 3:04PM CDT
Raptor Pharmaceuticals (Nasdaq:RPTP) today announced that Julie Anne Smith, Executive Vice President, Strategy and Chief Operating Officer at Raptor, has been named President and CEO-designate effective immediately. Smith will succeed Christopher Starr, Ph.D., as Chief Executive Officer and will join the Board effective January 1, 2015. As President and CEO-designate, Smith will oversee all company operations based out of Raptor's headquarters in Novato, California. Dr. Starr will continue working closely with Smith during this transition period, will remain on the Board of Directors and will consult on Raptor development projects following the succession.
Raptor Pharmaceutical Enters Into $70 Million Financing Transaction and Amended Loan Agreement With HealthCare Royalty Partners
GlobeNewswire - Tue Jul 01, 4:13PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has entered into agreements for $70 million in funding from HealthCare Royalty Partners (HC Royalty) and its affiliates in a private placement. The funding includes $60 million in new convertible senior notes and an additional $10 million of funding pursuant to an amended and restated loan agreement, originally signed on December 20, 2012. The new capital will be used for expansion of the company's manufacturing capacity, expansion of commercial operations in Europe, advancement of the company's development programs and general corporate purposes, including working capital. Closing is expected to occur by the end of July 2014 and is subject to customary closing conditions under both the convertible note financing agreement and the amended and restated loan agreement.
Are Investors Wrong About Raptor Pharmaceuticals?
George Budwell, The Motley Fool - Motley Fool - Thu Jun 26, 4:00PM CDT
A rapidly increasing short interest in a stock is sometimes a good signal that an investment may not be a good idea. Even so, it's critical to understand why shorts are moving into the stock before making any investment decisions. Raptor...
Data Published in Journal of Pediatrics Demonstrated That PROCYSBI(R) Improved Quality of Life and Preserved Kidney Function in Cystinosis Patients
GlobeNewswire - Tue Jun 24, 6:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that data from its open label extension study of delayed-release cysteamine bitartrate (PROCYSBI) has been published in the Journal of Pediatrics [DOI: 10.1016/j.jpeds.2014.05.013]. The study demonstrated that patients with nephropathic cystinosis who took PROCYSBI for two years were able to sustain optimal cystine control in their white blood cells and preserve kidney function over the long term, and had significant improvements in social, school and total functioning based on validated quality of life measurement scales.
FDA Approvals, Agreements, Investor Conference Schedules, and Technical Updates - Analyst Notes on Covidien, Pacira, Techne, OraSure and Raptor Pharmaceutical
PR Newswire - Tue Jun 17, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Techne Corp. (NASDAQ: TECH), OraSure Technologies Inc. (NASDAQ: OSUR) and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3789-100free.
Raptor Pharma (RPTP) is in Overbought Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 9:56AM CDT
Raptor Pharma (RPTP) is in Overbought Territory: What’s Next?
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
Raptor Pharmaceutical to Present at Upcoming Investor Conference in September
GlobeNewswire - Wed Aug 27, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 10, 2014 at 11:30 a.m. EDT/8:30 a.m. PDT. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.
Global Nonalcoholic Steatohepatitis (NASH) Market - Research Report to 2020
M2 - Mon Aug 18, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2l26vd/global) has announced the addition of the "Global Nonalcoholic Steatohepatitis (NASH) Market (Pipeline analysis, drug class, clinical trials and Geography) - Research Report, 2013 - 2020" report to their offering. A new report entitled, "Nonalcoholic Steatohepatitis Market (Pipeline analysis, drug class and Geography) Global Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013 - 2020", indicates that the global nonalcoholic steatohepatitis (NASH) market would reach $1.6 billion by 2020 registering CAGR of 25.6% from 2014 to 2020. The high prevalence of Type II diabetes and obesity, which lead to NASH and other non-alcoholic fatty liver diseases (NAFLD), would boost market growth. North America's heightened focus on NASH research has resulted in it accounting for nearly half of the global market. It is also the region with the maximum occurrences of NASH and other non-alcoholic fatty liver diseases. Europe ranks second in terms of the prevalence of NASH. The number of patients living with the diabetes worldwide is expected to soar from 371 million in 2012 to 552 million by 2030. This suggests that by 2030, there will be 3 new cases of diabetes every 10 seconds. "The rampant growth of diabetes and obesity has prompted pharmaceutical manufacturers to seek out novel pharmaceutical solutions to tap promising potential in NASH," states AMR analyst Roshan Deshmukh. "Instrumental initiatives and increasing clinical trials for the development of novel NASH therapeutics will steer its faster commercialization," adds the analyst. Key Topics Covered: CHAPTER 1 NTRODUCTION CHAPTER 2 EXECUTIVE SUMMARY CHAPTER 3 MARKET BEYOND: WHAT TO EXPECT BY 2025 CHAPTER 4 MARKET OVERVIEW CHAPTER 5 GLOBAL NONALCOHOLIC STEATOHEPATITIS MARKET BY DRUG TYPES CHAPTER 6 GLOBAL NONALCOHOLIC STEATOHEPATITIS MARKET (PIPELINE DRUG ANALYSIS)BY GEOGRAPHY, 2013-20206 CHAPTER 7 COMPANY PROFILES Companies Mentioned: - Enzo Biochem - Genfit - Gilead Science - Intercepts Pharmaceuticals - Novo Nordisk - Raptor Pharmaceutical Corp. For more information visit http://www.researchandmarkets.com/research/2l26vd/global
Raptor Pharmaceuticals (RPTP) Jumps: Stock Adds 28.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 8:39AM CDT
Raptor Pharmaceuticals Corp. (RPTP) was a big mover last session, as its shares rose over 28% on the day.
Why Raptor Pharmaceuticals (RPTP) Stock Is Gaining Today
at The Street - Fri Aug 08, 10:58AM CDT
Raptor Pharmaceuticals (RPTP) is gaining Friday after beating analysts' estimates for earnings and revenue in the second quarter and raising its sales guidance for the year.
Raptor Pharmaceutical Reports Second Quarter 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Global net product sales for PROCYSBI of $16.3 million reported for second quarter 2014
Raptor Pharmaceutical to Present at Upcoming Investor Conference
GlobeNewswire - Wed Aug 06, 3:51PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Canaccord Genuity Annual Growth Conference in Boston on Wednesday, August 13, 2014 at 5:00 p.m. EDT/2:00 p.m. PDT. Georgia Erbez, CFO of Raptor, will present an update on the company's commercial activities and clinical programs. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.
Raptor Receives Orphan Drug Designation for Cysteamine Bitartrate in Huntington's Disease From the European Commission
GlobeNewswire - Mon Aug 04, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the European Commission (EC) approved its application for orphan drug designation of cysteamine bitartrate, the active ingredient in RP103, for the treatment of Huntington's disease. The decision follows a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) in June. In February of this year, Raptor announced encouraging top line results from a planned 18-month analysis of the blinded, randomized, placebo-controlled phase of its ongoing CYST-HD clinical trial of RP103, its proprietary delayed release cysteamine bitartrate capsule, in patients with early-stage Huntington's disease.
The Federal Reserve Playing Analyst Damaging to Biotechnology Companies
ACCESSWIRE - Wed Jul 30, 9:06AM CDT
WHITEFISH, MT / July 30, 2014 / The July 15 U.S. Federal Reserve report on monetary policy touched off a barrage of barely polite and not very muted commentary from one end of the web to the other this past week with 32 simple words: "Equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched, with ratios of prices to forward earnings remaining high relative to historical norms." The release of the report to Congress coincided with the start of Federal Reserve Chairwoman Janet Yellen's testimony before a Congressional committee. NBI, the Nasdaq Biotechnology Index, slumped from around 2,700 on Tuesday to a low of 2,536 on Thursday, a 6% nosedive, before paring the losses with an up day on Friday. Of the 120 companies in the NBI, 101 closed in the red last week, including Ligand Pharma (NASDAQ: LGND) shedding 19.4% and Raptor Pharma (NASDAQ: RPTP) falling 18.7%.
Raptor Pharmaceutical to Hold Second Quarter 2014 Financial Results Webcast and Conference Call
GlobeNewswire - Mon Jul 28, 3:15PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release second quarter 2014 financial results after market close on Thursday, August 7, 2014. Raptor management will host a webcast and conference call at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update.
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic
ACCESSWIRE - Thu Jul 24, 9:03AM CDT
WHITEFISH, MT / July 24, 2014 / Fat is driving the bus these days in one narrow, but widening, biotech sector as companies strive for dominance. Among these are Galectin Therapeutics Inc. (NASDAQ: GALT), Intercept Pharmaceuticals (NASDAQ: ICPT), Raptor Pharmaceuticals (NASDAQ: RPTP) and Gilead Sciences (NASDAQ: GILD), all of which are in search of a cure for one stage or another of "fatty liver disease."
Executive Appointments and Technical Updates - Analyst Notes on Aeri Pharmaceuticals, DaVita, Prana Biotechnology, Raptor and Avanir Pharmaceuticals
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Aeri Pharmaceuticals, Inc. (NASDAQ: AERI), DaVita HealthCare Partners Inc. (NYSE: DVA), Prana Biotechnology Ltd. (NASDAQ: PRAN), Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) and Avanir Pharmaceuticals (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4726-100free.
3 Stocks Spiking on Unusual Volume
at The Street - Thu Jul 10, 8:14AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Raptor Pharmaceuticals CEO to Retire, Appoints Successor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 4:10PM CDT
Raptor Pharma (RPTP) announced a change at the helm.
Raptor Announces CEO Succession Plan; Dr. Christopher Starr to Retire as CEO at Year-end 2014, Julie Anne Smith Named President and CEO-Designate
GlobeNewswire - Mon Jul 07, 3:04PM CDT
Raptor Pharmaceuticals (Nasdaq:RPTP) today announced that Julie Anne Smith, Executive Vice President, Strategy and Chief Operating Officer at Raptor, has been named President and CEO-designate effective immediately. Smith will succeed Christopher Starr, Ph.D., as Chief Executive Officer and will join the Board effective January 1, 2015. As President and CEO-designate, Smith will oversee all company operations based out of Raptor's headquarters in Novato, California. Dr. Starr will continue working closely with Smith during this transition period, will remain on the Board of Directors and will consult on Raptor development projects following the succession.
Raptor Pharmaceutical Enters Into $70 Million Financing Transaction and Amended Loan Agreement With HealthCare Royalty Partners
GlobeNewswire - Tue Jul 01, 4:13PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has entered into agreements for $70 million in funding from HealthCare Royalty Partners (HC Royalty) and its affiliates in a private placement. The funding includes $60 million in new convertible senior notes and an additional $10 million of funding pursuant to an amended and restated loan agreement, originally signed on December 20, 2012. The new capital will be used for expansion of the company's manufacturing capacity, expansion of commercial operations in Europe, advancement of the company's development programs and general corporate purposes, including working capital. Closing is expected to occur by the end of July 2014 and is subject to customary closing conditions under both the convertible note financing agreement and the amended and restated loan agreement.
Are Investors Wrong About Raptor Pharmaceuticals?
George Budwell, The Motley Fool - Motley Fool - Thu Jun 26, 4:00PM CDT
A rapidly increasing short interest in a stock is sometimes a good signal that an investment may not be a good idea. Even so, it's critical to understand why shorts are moving into the stock before making any investment decisions. Raptor...
Data Published in Journal of Pediatrics Demonstrated That PROCYSBI(R) Improved Quality of Life and Preserved Kidney Function in Cystinosis Patients
GlobeNewswire - Tue Jun 24, 6:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that data from its open label extension study of delayed-release cysteamine bitartrate (PROCYSBI) has been published in the Journal of Pediatrics [DOI: 10.1016/j.jpeds.2014.05.013]. The study demonstrated that patients with nephropathic cystinosis who took PROCYSBI for two years were able to sustain optimal cystine control in their white blood cells and preserve kidney function over the long term, and had significant improvements in social, school and total functioning based on validated quality of life measurement scales.
FDA Approvals, Agreements, Investor Conference Schedules, and Technical Updates - Analyst Notes on Covidien, Pacira, Techne, OraSure and Raptor Pharmaceutical
PR Newswire - Tue Jun 17, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Techne Corp. (NASDAQ: TECH), OraSure Technologies Inc. (NASDAQ: OSUR) and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3789-100free.
Raptor Pharma (RPTP) is in Overbought Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 9:56AM CDT
Raptor Pharma (RPTP) is in Overbought Territory: What’s Next?
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
